ASHLEY SYDNOR: Open Payments
NPI 1750996930 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$393 in 19 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $138 · 2025 $393
Food & beverage: $393
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 5 | $95 |
| Tris Pharma Inc | 3 | $71 |
| ABBVIE INC. | 4 | $64 |
| Almatica Pharma LLC | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: Dyanavel XR, VRAYLAR, LOREEV XR, VIVITROL, ARISTADA, REXULTI, ABILIFY MAINTENA, Qelbree.
Industry payments across MD — which companies pay providers there.
